2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-126354
    Palmitoyldocosahexaenoyl phosphatidylcholine 59403-54-2 99.56%
    Palmitoyldocosahexaenoyl phosphatidylcholine is an endogenous metabolite.
    Palmitoyldocosahexaenoyl phosphatidylcholine
  • HY-134161
    DL-α-(Difluoromethyl)arginine 69955-43-7
    DL-α-(Difluoromethyl)arginine is an potent, enzyme-activated and irreversible arginine decarboxylases inhibitor. DL-α-(Difluoromethyl)arginine blocks the arginine decarboxylase activity of E.coli and Pseudomonas aeruginosa in vivo.
    DL-α-(Difluoromethyl)arginine
  • HY-148978
    18:0,18:1 PS sodium 321883-23-2 99.70%
    18:0,18:1 PS sodium is the dominant phosphatidylserine subtype in cells, exosomes and HIV particles. It is abundant in the brain and is essential for maintaining membrane structure, lipid raft organization and intracellular trafficking. 18:0,18:1 PS sodium mediates interleaflet membrane coupling through cholesterol-dependent interactions with very long-chain sphingolipids, and can induce the clustering of glycosylphosphatidylinositol-anchored proteins. In addition, clusters formed by the binding of 18:0,18:1 PS sodium to cholesterol not only facilitate the proper distribution of cholesterol in lipid bilayers, but also effectively protect cholesterol from oxidative damage.
    18:0,18:1 PS sodium
  • HY-U00257
    AZD1979 1254035-84-1 99.59%
    AZD1979 is a Melanin-concentrating hormone receptor 1 (MCHr1) antagonist with an IC50 of ~12 nM.
    AZD1979
  • HY-112790R
    Adenosylcobalamin (Standard) 13870-90-1 98.32%
    Adenosylcobalamin (Standard) is the analytical standard of Adenosylcobalamin. This product is intended for research and analytical applications. Adenosylcobalamin (Coenzyme B12;Cobamamide;AdoCbl) is an active form of Vitamin B12 which is a cofactor for methylmalonyl CoA mutase
    Adenosylcobalamin (Standard)
  • HY-W013707
    Cytidine-5'-triphosphate disodium dihydrate 81012-87-5
    Cytidine-5'-triphosphate disodium dihydrate (5'-CTP disodium dihydrate) is a molecule of high energy, and acts as a coenzyme in glycerophospholipid biosynthesis and protein glycosylation.
    Cytidine-5'-triphosphate disodium dihydrate
  • HY-W017692
    2-Aminoindan-2-phosphonic acid hydrochloride 1416354-35-2
    2-Aminoindan-2-phosphonic acid hydrochloride is a competitive phenylalanine ammonia lyase (PAL) inhibitor that significantly decreases the levels of total phenolic compounds and PheGs in plant cultured cells.
    2-Aminoindan-2-phosphonic acid hydrochloride
  • HY-W176199
    DPPD-Q 3421-08-7 ≥98.0%
    DPPD-Q is a quinone derivative of p-phenylenediamine antioxidants and an analog of DTPD-Q (HY-163650). DPPD-Q is identified as a major sewage treatment plant effluent.
    DPPD-Q
  • HY-W414591
    L-alpha-lysophosphatidylcholine, lauroyl 20559-18-6 99.82%
    L-alpha-lysophosphatidylcholine, lauroyl (1-Lauroyl-2-hydroxy-sn-glycero-3-phosphatidylcholine) is an ester product.
    L-alpha-lysophosphatidylcholine, lauroyl
  • HY-W423191
    Maltobionic acid 534-42-9
    Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H2O2)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation.
    Maltobionic acid
  • HY-W040329R
    2'-Deoxyadenosine (Standard) 958-09-8 99.94%
    2'-Deoxyadenosine (Standard) is the analytical standard of 2'-Deoxyadenosine (HY-W040329). This product is intended for research and analytical applications. 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer.
    2'-Deoxyadenosine (Standard)
  • HY-19919
    BMS-779788 918348-67-1 99.57%
    BMS-779788 is a LXR partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.
    BMS-779788
  • HY-B2223
    Thiamine nitrate 532-43-4 99.84%
    Thiamine nitrate is an essential vitamin which can enhance normal neuronal actives.
    Thiamine nitrate
  • HY-P1348
    GLP-1 moiety from Dulaglutide 1197810-60-8 99.60%
    GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury.
    GLP-1 moiety from Dulaglutide
  • HY-103478
    KHK-IN-2 2135304-43-5 99.05%
    KHK-IN-2 is a potent and selective ketohexokinase (KHK) inhibitor with an IC50 of 0.45 μM.
    KHK-IN-2
  • HY-108257
    Atorvastatin sodium 134523-01-6 99.85%
    Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin sodium
  • HY-112443
    AZD3458 2132961-46-5 99.71%
    AZD3458 is a potent and remarkably selective PI3Kγ inhibitor with pIC50s of 9.1, 5.1, <4.5, and 6.5 for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively.
    AZD3458
  • HY-125990
    SLC13A5-IN-1 2227548-95-8 98.62%
    SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.
    SLC13A5-IN-1
  • HY-143200
    OSBPL7-IN-1 1269826-44-9 99.84%
    OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.
    OSBPL7-IN-1
  • HY-108022A
    Azemiglitazone potassium 1314533-27-1 98.94%
    Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide.
    Azemiglitazone potassium
Cat. No. Product Name / Synonyms Application Reactivity